eFFECTOR Therap 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases  1 Product   4 Trials   12 News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zotatifin (eFT226) / eFFECTOR Therap
NCT03675893: RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer

Recruiting
2
130
US
Letrozole, Femara, Abemaciclib, Verzenio, LY3023414, Metformin, Glucophage, Zotatifin, eFT226
Dana-Farber Cancer Institute, Eli Lilly and Company, Effector Therapeutics
Endometrial Cancer, Ovarian Cancer
08/26
08/29
NCT05101564: Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer

Active, not recruiting
2
19
US
Alpelisib, Piqray, BYL719, Tamoxifen, Soltamox, TAM, Zotatifin, eFT226, Fulvestrant, Faslodex
Stanford University, United States Department of Defense
Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer
09/25
12/26
NCT04092673: Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

Recruiting
1/2
30
US
eFT226, Selective translation inhibitor, Sotorasib, Lumarkus, Fulvestrant, Faslodex, Abemaciclib, Verzenia, Trastuzumab, Herceptin
Effector Therapeutics
Solid Tumor, Adult
12/24
03/25
PROPEL, NCT04632381: Intravenous Zotatifin in Adults With Mild or Moderate COVID-19

Completed
1b
36
US
Zotatifin, Zota, Placebo, PBO
Effector Therapeutics, Medpace, Inc.
Corona Virus Infection
01/23
09/23
tomivosertib (eFT508) / eFFECTOR Therap
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC
Active, not recruiting
2
68
US, RoW
Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®
Effector Therapeutics, Medpace, Inc., ICON plc
Non-small Cell Lung Cancer
10/24
12/24
NCT05744739: Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)

Active, not recruiting
1
15
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Tomivosertib, EFT-508, eFT508, Spiro(cyclohexane-1,3'(2'H)-imidazo(1,5-a)pyridine)-1',5'-dione, 6'-((6-Amino-4-pyrimidinyl)amino)-8'-methyl-
Northwestern University, National Cancer Institute (NCI), EFFECTOR Therapeutics, Inc.
Acute Myeloid Leukemia
04/29
04/30
Undisclosed eIF4E inhibitor / Pfizer, eFFECTOR Therap
No trials found

Download Options